IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm
Completed · Phase 3 · Has a placebo group
Conditions studied: Blepharospasm
In brief
Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline. Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.
Key facts
- Study ID
- NCT00406367
- Run by
- Merz Pharmaceuticals GmbH
- People needed
- 109
- Starts
- 2006-10-01
- Expected to finish
- 2009-07-01
- Last updated by the study team
- 2013-03-15
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Baylor College of Medicine — Houston, Texas, United States
- David King, MD - Private Practice — Halifax, Nova Scotia, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.